Intellectual Property, Patents & Technology Transfer Sagar Manoli Shashidhar, Philippe Abdel-Sayed Responsible Conduct in Biomedical Research EPFL, 12.11.2010.

Slides:



Advertisements
Similar presentations
September 21, 2006 DePaul University, Chicago, IL APLF- DePaul University College of Law 2006 Symposium on Intellectual Property Law.
Advertisements

Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
Industrial Property the Patent system
Intellectual Property Rights (IPR)
Noha Mahmoud Lecturer of Clinical Pharmacy. Course Description This course is one credit hour course given during level 1. It gives idea about pharmacy,
Proteomics and “Orphan” Receptors Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
The patentability of biotechnological inventions: The European Commission’s second 16c report Paul Van den Bulck Partner at Ulys Law Firm (Brussels) Lecturer.
Intellectual Property March 4, 2015 Don Keach Director, Intellectual Property Development and Technology Transfer Office Copyright University of Kentucky.
1 Single Nucleotide Polymorphisms (SNP) Gary Jones SPE, Technology Center 1600 (703)
Biotechnology Unit 3.04.
Ownership and distribution Ethical issues in patenting Pr Samia Hurst Institute for Biomedical Ethics University of Geneva Medical School.
What Do Toxicologists Do?
1 1 AIPLA Firm Logo American Intellectual Property Law Association Myriad Guidance for Biotechnology and Chemical Practice Joerg-Uwe Szipl Griffin and.
Intellectual Property Overview for the Academic Researcher AMSTER ROTHSTEIN & EBENSTEIN LLP December 9, 2008 Kenneth George.
Prometheus & Myriad The Future of Diagnostic & Gene Claims Mercedes Meyer, Ph.D. Kevin Noonan, Ph.D.
Intellectual Property – Why it Matters
Careers in Biotechnology
Chapter 6 – Legal Issues for the Entrepreneurs Vishnu Parmar, IBA University of Sindh, Jamshoro.
EPIP 2 Research Tools in Genetics Sandy Thomas Nuffield Council on Bioethics November 2003.
Understanding patent claims (f) Drug for the treatment of cancer.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
15.4 Ethics and Impacts of Biotechnology
PRINCIPLES OF BIOTECHNOLOGY
A Basic Primer on Intellectual Property Kathryn Atchison, DDS, MPH Vice Provost, Intellectual Property and Industry Relations Associate Vice Chancellor.
INTELLECTUAL PROPERTY PROTECTION OF BIOTECH IN THE U.S. Marc S. Friedman Chair, Intellectual Property Practice Sills Cummis Epstein & Gross P.C. 30 Rockefeller.
Intellectual property Week 19 Tom Underhill. Intellectual property Patents Registered designs/design rights Case study/Questions/update (DA). Details:
Biotech Inventions in Latin America Argentina Ignacio Sánchez Echagüe Marval, O’Farrell & Mairal.
Page 1 IOP Genomics Workshop Patents and Patenting Biotech Inventions Annemieke Breukink, Ph.D. September 8th, 2009.
Intellectual Property Rights Margaret Lawlor Business Development Manager Faculty of Medical Sciences 3rd October 2013 copyright©NewcastleUniversity 2013.
Lesson Overview Lesson Overview Studying the Human Genome Lesson Overview 14.3 Studying the Human Genome.
DNA Technology.
Knowledge Transfer | Accelerating Innovation KT Training – 9 September 2014 Introduction to Intellectual Property Rights D. Mazur – 9 September 2014.
A symposium presented by the IUPS Ethics Committee 37 th Congress IUPS Birmingham UK July 2013.
Patents and Medicines: How the system has discouraged innovation and reduced patient access to benefits of knowledge GREG PERRY Director General, EGA World.
Introduction to Patents Anatomy of a Patent & Procedures for Getting a Patent Margaret Hartnett Commercialisation & IP Manager University.
Access to Genetic Resources & Traditional Knowledge The Bellagio compulsory cross-licensing proposal for benefit sharing consistent with more competition.
1 Written Description Analysis and Capon v. Eshhar Jeffrey Siew Supervisory Patent Examiner AU 1645 USPTO (571)
Patents Business of Biotechnology BIT 120. Definition Patent Government grants which provide inventors with right to exclude others from practicing invention.
Intellectual Property: Patent Eligible Subject Matter Prof. Peng
© 2011 Dannemann Siemsen. Todos os direitos reservados. Biotech IP issues in Brazil Gustavo Morais May 2011 Gustavo Morais May 2011.
Synthetic Biology: Caught between Property Rights, the Public Domain, and the Commons Nahum Seifeselassie May 16, 2012.
© J. Straus Patenting of Genes and Life Forms, and the impact of Patenting on Upstream Science Joseph Straus, Munich WIPO Open Forum on the Draft.
Patentability Considerations in the 3-D Structure Arts Patentability Considerations in the 3-D Structure Arts Michael P. Woodward Supervisory Patent Examiner.
 HS-LS1-1. Construct an explanation based on evidence for how the structure of DNA determines the structure of proteins which carry out the essential.
Intellectual Property Rights and Pharmaceutical Industry
Ownership of Software Software represents the results of intellectual rather than purely physical efforts and is therefore inherently non- tangible. So.
Law and Policy of Relevance to the Management of Plant Genetic Resources Session 7: IPRs II: How Intellectual Property Rights Can Affect the Daily.
Law and Policy of Relevance to the Management of Plant Genetic Resources Objectives of Day Four 1.To discuss and understand how intellectual property.
Examination Practice in Applications Presenting “Reach-Through Claims” George Elliott Practice Specialist Technology Center 1600
Myriad The Future of DNA Claims Mercedes Meyer, Ph.D., JD AIPLA 1.
Patent Innovation Christine Chen 9/15/2008.  In general, patents must be:  Novel (not known previously) genetic sequences  Non-obvious (not just a.
PATENTS, INTEGRATED CIRCUITS, AND INDUSTRIAL DESIGNS Presented By: Navdeep World Trade Organization.
Bio-technology.  Proving bread with leaven prehistoric  Alcoholic drinks from fermented juices prehistoric  Vinegar from fermented juices prehistoric.
CHAPTER 20 BIOTECHNOLOGY. Biotechnology – the manipulation of organisms or their components to make useful products Biotechnology is used in all facets.
Introduction The Patentability of Human Genes Is patenting human genes moral? Should it be legal? Should there be international intervention?
Intellectual property (IP) - What is it?. Intellectual property (IP) Refers to creations of the mind, such as inventions; literary and artistic works;
Patent Review Overview Summary of different types of Intellectual Property What is a patent? Why would you want one? What are the requirements for patentability?
What is Biotechnology? How Long have humans used Biotechnology?
VISHAAL HARISARAN Intellectual Property Rights in Animal Breeding and Genetics.
Be Safe: when experimenting and disposing of waste.
Ip4inno 1 Content of the module IP for the creative industries Patented computer-implemented inventions Software Biotechnological inventions.
DIAGNOSIS OF DISEASES AND GENE THERAPY
Intellectual Property & Contemporary Issues of Biotechnology Law
Genetic Engineering and Animal Research
Careers in Biotechnology
Challenges in Biomedical Technology
What is Biomedical Research?
What is Biomedical Research?
Careers in Biotechnology
Gene Patenting Connecticut Invention Convention
Presentation transcript:

Intellectual Property, Patents & Technology Transfer Sagar Manoli Shashidhar, Philippe Abdel-Sayed Responsible Conduct in Biomedical Research EPFL,

Overview The eligibility to patent genes Economical, Legal & Ethical considerations in Biotech IP

Example of claims in Biotech We managed to identify, purify and sequence the following new peptide sequence: GTEAATGAGMFLEATPMLSIPPE Moreover, we have demonstrated its function as an inhibitor of prostate cancer. What could we claim in this case?

Claims Answers 1.The peptide sequence: GTEAATGAGMFLEATPMLSIPPE 2.The nucleotide sequence coding the peptide according to claim 1 3.The vector comprising one or more copies of the sequence according to claim 2 4.The synthesis process of the peptide according to claim 1 characterized by the steps :...( chemical synthesis or recombinant peptide) 5.Peptide obtained by the process according to claim 4

Claims Answers 6. The pharmaceutical composition containing as active molecule the peptide according to claim 1 7. The peptide according to claim 1 as a drug 8. The use of the peptide according to claim 1, for the manufacture of a drug for the treatment of prostate cancer 9. The treatment method of prostate cancer characterized by the injection in patient of the pharmaceutical composition according to claim The kit comprising as active molecule the peptide according to claim 1 in combination with physiologic liquid and usage instructions

Eligibility to patent genes So far, – Plants and animals are in principle patentable – But, plant and animal varieties are not patentable – Isolated biological material (including an element isolated from the human body or otherwise produced by means of a technical process, including sequence or partial sequence of a gene) may be patentable even if identical to material in nature The New York Times, October 29, 2010 « U.S. Says Genes Should Not Be Eligible for Patents» by Andrew Pollack

« U.S. Says Genes Should Not Be Eligible for Patents» Genes are products of nature, not inventions, and should be common heritage of mankind. Criteria for patentability – New – Non-obvious – Useful

Discussion Human and other genes should not be eligible for patents because they are part of nature? This new position of the government would have a limited impact on biotech industry? Patenting system is vital to the development of Biotech industry?

Case study-Ruling on BRCA gene patents BRCA 1 &2 are tumour suppressor genes. They were patented by Myraid genetics, a molecular diagnostic company. Parts of the patent (only DNA sequence and NOT downstream products from it) were ruled invalid by district judge. Medical associations, doctors and patients were suing the company.

Reasons for invalidating the patent: 1)Because of long-standing concerns in scientific community that gene patents inhibit research and slow innovation. 2)Just diagnostics !! No development on the drug development was going on !! 3)Diagnostic cost went from $1600 to $3100 and denied women from getting tested because of inadequate insurance coverage. 4)Of course, it is a product of nature.

Consequences of invalidating the patent: Negatives: 1)Direct impact on the other companies having patents on genes associated with genetic tests. 2)Without IPR companies don’t get money and interesting discoveries sit on the shelf. Positives: 1)Further research and reduction in diagnostic costs 2)Sharing of individual test results with patients

Economical Issues Disagreement with gene patenting They restrain additional research because of dependency on patented genes. Delayed innovation and possible future litigation May impede the growth and development of new and uncharted areas in the emerging field, for ex Celera’s IP impeded 30% growth in research and product development. Agreement with gene patenting Critical to protect innovation Costs associated with imitating a product are extremely low relative to the innovator’s costs for discovering and developing it. Prevents doctors and geneticists from performing these tests for profit, or in a way that competes with the patent holder, without reimbursement to the inventors of those tests

Legal Issues Disagreement with gene patenting Nature’s products ! “The useful properties of a gene’s sequence are natural, inherent properties of the genes themselves”. Gene functions are obvious: can be predicted through in silico analysis on the basis of their homology to other genes.” Agreeing with gene patenting Many biotechnology products are built upon compounds existing in nature including antibiotics, interferons, interleukins, and insulin. Can be patented as long as inventor shows how to enable and use it.

Ethical Issues Disagree with gene patenting -Someone else is a owner of patient's genes. -Prevents access to the testing procedures. -Limitation of information exchange (the traditional pathway by which medical knowledge is advanced and shared) in the medical use. Agree with gene patenting -Person does not own any tissues or cells once they are outside the person’s body. -There is no evidence of patients unable to utilize existing genetic tests because of patents.

Thank You !